UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Microstructures and mechanical properties of the in situ TiB–Ti metal–matrix composites synthesized by spark plasma sintering process

Journal of alloys and compounds, 2011-07, Vol.509 (29), p.7692-7696

2011

Volltextzugriff (PDF)

A new rapid route to in-situ synthesize TiB–Ti system functionally graded materials using spark plasma sintering method

Materials science & engineering. A, Structural materials : properties, microstructure and processing, 2013-03, Vol.565, p.326-332

2013

Volltextzugriff (PDF)

Microstructure and mechanical properties of TiB-TiB2 ceramic matrix composites fabricated by spark plasma sintering

Materials science & engineering. A, Structural materials : properties, microstructure and processing, 2011-04, Vol.528 (10-11), p.3849-3853

2011

Volltextzugriff (PDF)

A New Rapid Route for In Situ Synthesizing Monolithic TiB Ceramic

Journal of the American Ceramic Society, 2011-09, Vol.94 (9), p.2754-2756

2011

Volltextzugriff (PDF)

Microstructure and mechanical properties of TiB–TiB 2 ceramic matrix composites fabricated by spark plasma sintering

Materials science & engineering. A, Structural materials : properties, microstructure and processing, 2011, Vol.528 (10), p.3849-3853

2011

Volltextzugriff (PDF)

Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3501-3508

2013

Volltextzugriff (PDF)

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation

Future oncology (London, England), 2020-05, Vol.16 (15), p.975-989

2020

Volltextzugriff (PDF)

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024-05, Vol.27 (3), p.558-570

2024

Volltextzugriff (PDF)

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Journal of clinical oncology, 2012-04, Vol.30 (10), p.1114-1121

2012

Volltextzugriff (PDF)

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

The Lancet (British edition), 2023-09, Vol.402 (10408), p.1133-1146

2023

Volltextzugriff (PDF)

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1637-1651

2017

Volltextzugriff (PDF)

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

The Lancet (British edition), 2023-11, Vol.402 (10415), p.1835-1847

2023

Volltextzugriff (PDF)

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

The lancet oncology, 2022-11, Vol.23 (11), p.1430-1440

2022

Volltextzugriff (PDF)

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Journal of experimental & clinical cancer research, 2022-06, Vol.41 (1), p.189-189, Article 189

2022

Volltextzugriff (PDF)

Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024-09, Vol.27 (5), p.1046-1057

2024

Volltextzugriff (PDF)

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

The lancet. Gastroenterology & hepatology, 2021-08, Vol.6 (8), p.649-658

2021

Volltextzugriff (PDF)

Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4002-4002

2023

Volltextzugriff (PDF)

IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

Journal of hepatology, 2023-06, Vol.78, p.S9-S10

2023

Volltextzugriff (PDF)

GS-011 - IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

Journal of hepatology, 2023-06, Vol.78, p.S9-S10

2023

Volltextzugriff (PDF)

Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4045-4045

2024

Volltextzugriff (PDF)

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4010-4010

2019

Volltextzugriff (PDF)

KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4014-4014

2023

Volltextzugriff (PDF)

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study

EClinicalMedicine, 2022-12, Vol.54, p.101679-101679, Article 101679

2022

Volltextzugriff (PDF)

A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394

Liver cancer (Basel ), 2024-08, Vol.13 (4), p.389-400

2024

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(17)
Humans
(14)
Oncology
(13)
Adult
(9)
Female
(9)
Male
(9)
Middle Aged
(8)
Patients
(8)
Tumors
(8)
Aged
(7)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Technology
(6)
Cancer Therapies
(5)
Chemotherapy
(5)
Double-Blind Method
(5)
Gastroenterology & Hepatology
(5)
Hepatocellular Carcinoma
(5)
Liver Cancer
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Microstructures and mechanical properties of the in situ TiB–Ti metal–matrix composites synthesized by spark plasma sintering process

A new rapid route to in-situ synthesize TiB–Ti system functionally graded materials using spark plasma sintering method

Microstructure and mechanical properties of TiB-TiB2 ceramic matrix composites fabricated by spark plasma sintering

A New Rapid Route for In Situ Synthesizing Monolithic TiB Ceramic

Microstructure and mechanical properties of TiB–TiB 2 ceramic matrix composites fabricated by spark plasma sintering

Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

GS-011 - IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study

KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study

A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394

Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study

Suchergebnisse filtern